PMID- 28929449
OWN - NLM
STAT- MEDLINE
DCOM- 20181023
LR  - 20181023
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 167
IP  - 1
DP  - 2018 Jan
TI  - Concordance analysis of paired cancer antigen (CA) 15-3 and 27.29 testing.
PG  - 269-276
LID - 10.1007/s10549-017-4513-0 [doi]
AB  - PURPOSE: Cancer antigens (CA) 15-3 and 27.29 are used in the clinical management 
      of many breast cancer patients. Given that immunoassays for CA 15-3 and CA 27.29 
      target epitopes on the same glycoprotein-Mucin 1 (MUC1)-the present analysis was 
      conducted to evaluate the potential concordance of tumor marker results when both 
      tests were ordered by providers on the same specimens. METHODS: A retrospective 
      limited dataset of paired CA 15-3 (Roche Diagnostics) and CA 27.29 (Siemens 
      Diagnostics) test results was obtained from a national clinical reference 
      laboratory. Concordance according to reference interval (RI) status and percent 
      (%) change between consecutive test results was analyzed. RESULTS: 37,652 paired 
      results from 12,470 distinct patients were obtained. The correlation between CA 
      15-3 and CA 27.29 results was high (correlation coefficient: Pearson, 0.967), 
      although across the dataset a significant difference between CA 15-3 and CA 27.29 
      results was observed (P < 0.05). RI concordance between CA 15-3 and CA 27.29 
      results was observed in 93.7% of pairs (35,280 of 37,652). Correlation was also 
      observed in the % change of CA 15-3 and CA 27.29 results between consecutive 
      specimens for individual patients. Using doubling or halving thresholds (i.e., 
      100% increase or 50% decrease), concordance in % change was observed between CA 
      15-3 and CA 27.29 in approximately 90% of cases. Individual patient results 
      trended similarly across both markers over time. CONCLUSION: While generally 
      concordant, CA 15-3 and CA 27.29 results should not be used interchangeably. The 
      present report provides no evidence for added value in performing both tests 
      routinely for individual patients.
FAU - Lin, David C
AU  - Lin DC
AD  - ARUP Laboratories, Department of Pathology, University of Utah, 500 Chipeta Way, 
      MC 115, Salt Lake City, UT, 84108, USA.
AD  - Department of Pathology and Laboratory Medicine, Ann & Robert H. Lurie Children's 
      Hospital of Chicago, Northwestern University Feinberg School of Medicine, 
      Chicago, IL, USA.
FAU - Genzen, Jonathan R
AU  - Genzen JR
AD  - ARUP Laboratories, Department of Pathology, University of Utah, 500 Chipeta Way, 
      MC 115, Salt Lake City, UT, 84108, USA. jonathan.genzen@path.utah.edu.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170919
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Antigens, Tumor-Associated, Carbohydrate)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CA 27-29 antigen)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Tumor-Associated, Carbohydrate/*blood
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/*blood/genetics/pathology
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Mucin-1/*blood/genetics
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Breast cancer
OT  - CA 15-3
OT  - CA 27.29
OT  - Cancer antigen
OT  - Mucin
OT  - Tumor marker
EDAT- 2017/09/21 06:00
MHDA- 2018/10/24 06:00
CRDT- 2017/09/21 06:00
PHST- 2017/09/10 00:00 [received]
PHST- 2017/09/13 00:00 [accepted]
PHST- 2017/09/21 06:00 [pubmed]
PHST- 2018/10/24 06:00 [medline]
PHST- 2017/09/21 06:00 [entrez]
AID - 10.1007/s10549-017-4513-0 [pii]
AID - 10.1007/s10549-017-4513-0 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2018 Jan;167(1):269-276. doi: 10.1007/s10549-017-4513-0. 
      Epub 2017 Sep 19.